Objective: The Palivizumab Outcomes Registry contains data on infants and young children who received palivizumab for the prevention of respiratory syncytial virus (RSV) that causes serious lower respiratory tract illness.
Introduction
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections (LRI), particularly bronchiolitis, in infants and young children. 1 In the United States, RSV-associated bronchiolitis has been estimated as the cause of up to 126 300 hospitalizations annually for children younger than 5 years 1 and is the leading cause of hospitalization for infants younger than 1 year. 2 The RSV-associated all-cause mortality rate is 5.4 per 100 000 person-years for infants younger than 1 year. 3 Infants with prematurity, chronic lung disease (CLD) and congenital heart disease (CHD) are more likely to experience increased morbidity and mortality from RSV infection compared to their full-term healthy peers.
2,4-6 Independent risk factors for severe RSV LRI or RSV hospitalization among infants born at 33 to 35 weeks' gestation include birth in the first half of the RSV season, preschool or school-aged siblings and household crowding. [7] [8] [9] Data are controversial regarding male sex, child-care attendance, limited breast-feeding, tobacco smoke exposure, and multiple births, with some studies demonstrating an increased risk of RSV hospitalization among these subgroups, 7, 8, 10 and others showing no effect. 11, 12 Synagis (palivizumab; MedImmune, Gaithersburg, MD, USA), a humanized murine monoclonal antibody with neutralizing and fusion-inhibitory activity against RSV, is approved by the Food and Drug Administration (FDA) for the prevention of serious LRI caused by RSV in pediatric subjects at high risk of RSV disease. In a clinical study of children born at 35 weeks' gestation or earlier and aged 6 months or younger and those 2 years or younger with CLD requiring medical therapy, palivizumab reduced the incidence of RSV-associated hospitalizations by 55% (P ¼ 0.00004) compared to placebo. 13 In another study, palivizumab reduced RSV-related hospitalizations by 45% (P ¼ 0.003) in infants and young children with hemodynamically significant CHD. 14 In both trials, monthly prophylaxis with palivizumab was well tolerated, with associated adverse events similar to those reported for placebo. 13, 14 Compared with the FDA-approved indicated populations, the guidelines published by the American Academy of Pediatrics (AAP) in 1998 limited their recommendations for prophylaxis with palivizumab to children <2 years of age with CLD who required medical therapy for their CLD within 6 months before the RSV season, infants born at 32 weeks' gestation or earlier without CLD and infants born between 32 and 35 weeks' gestation with the presence of additional medical or environmental factors, including anticipated heart surgery, the availability and proximity of hospital care, child-care attendance, exposure to tobacco smoke, the number of young siblings and underlying conditions that predisposed the infants to respiratory infection. 15 At that time, no specific recommendations were made for RSV prophylaxis with palivizumab of children with CHD. Additional modifications to the guidelines were made by the AAP in 2003 and the 2006 Red Book regarding infants born between 32 and 35 weeks' gestation. Prophylaxis with palivizumab was recommended for infants born between 32 and 35 weeks' gestation only if they were <6 months of age at the start of the RSV season and if X2 additional risk factors, that is, child-care attendance, congenital airway abnormalities, exposure to environmental air pollutants, school-aged siblings or severe neuromuscular disease, were present. 16, 17 Restricted child-care attendance and restricted exposure to tobacco smoke were recommended for this age group. Infants and children aged p24 months with hemodynamically significant CHD were also recommended for RSV prophylaxis with palivizumab.
The Palivizumab Outcomes Registry was established in 2000 to prospectively collect data on any child receiving RSV prophylaxis with palivizumab at any of the registry sites in the United States. The registry data collection process evolved as the AAP guidelines were updated. Registry data from the 2000 to 2001 and 2001 to 2002 RSV seasons have previously been reported. 18, 19 Data regarding infants with CHD were collected from the beginning of the registry and have been reported elsewhere. 20 In anticipation of changes in the recommendations for patients with CHD, beginning with the 2002 to 2003 season, additional data were collected on CHD as an additional risk factor. Because the registry was an ongoing effort, this large nationwide data set enables us to observe post-licensure patterns of palivizumab use and hospitalization rates among infants receiving immunoprophylaxis over time. As outlined above, previous reports described subsets of these data. This report represents the cumulative summary of four consecutive RSV seasons (2000 to 2001 through 2003 to 2004) and is the largest, most comprehensive data set regarding RSV prophylaxis in a realworld setting to date.
Methods

Enrollment
The Palivizumab Outcomes Registry is a prospective, observational registry designed to collect data on the demographics, clinical characteristics and outcomes of infants and young children who received palivizumab for prophylaxis of serious LRI caused by RSV from 2000 to 2004. Decisions regarding prophylaxis were made by the health-care provider at each site. Eligible sites included those that were able to meet project and subject recruitment timelines and provide all data points, specifically, hospitalization data; had previous experience with palivizumab and provided institutional review board approval of the study protocol. A total of 256 unique pediatric sites from across the United States participated during one or more seasons. The sites were distributed throughout 41 states and the District of Columbia. Before subject enrollment, parents or legal guardians were required to provide written informed consent for data collection and evaluation.
Infants and young children were eligible for enrollment at a participating site if they received their first dose of palivizumab for RSV prophylaxis during the periods described in Table 1 . Decisions for RSV prophylaxis were made at the discretion of the health-care provider. If the first dose was administered in the hospital before the initial birth discharge, enrollment occurred at the time of the subsequent dose at the participating pediatric office, clinic or at home. Subjects receiving doses in more than one season were counted as separate enrollments. There were no exclusion criteria other than lack of consent. 18 We sought to enroll 2500 subjects for the first season, approximately 5000 subjects for the second and third seasons, and 6500 subjects for the fourth season; to be representative of real-world palivizumab use in the United States.
Data collection
Data from each subject's medical record were entered into the registry data form by on-site personnel at enrollment with the first palivizumab injection, at the time of each subsequent injection, and for RSV hospitalization. Information recorded at the enrollment visit included demographics (race, age, weight, gestational age at birth and multiple birth status), medical history (neonatal intensive care unit (NICU) admission at birth and presence of CLD, CHD or cystic fibrosis), environmental history (the number of children and adults in the household, child-care enrollment (subject or other household children), and exposure to tobacco smoke) and the type of medical insurance. Congenital airway abnormalities or severe neuromuscular disease were also noted in these latter two seasons. In the last season, the primary diagnosis prompting RSV prophylaxis in subjects born after 35 weeks' gestation also was recorded. Data regarding date, dose and administration setting (that is, NICU, clinic/office, home or hospital) for each palivizumab injection administered during the RSV season were prospectively collected through April 30 for the first three seasons and through May 31 for the 2003 to 2004 season. Data on hospitalization and medical course during hospitalization (for example, oxygen, intensive care unit admission) for a primary or secondary RSV infection were prospectively collected through May 31 of each season. 18, 19 An RSV hospitalization, which is defined as any hospitalization with a duration of 24 h or longer for which RSV infection was confirmed by virology testing (for example, rapid antigen detection, viral culture), was directly reported to the on-site registry coordinator. Testing for RSV was performed locally at the discretion of the health-care provider; no confirmatory testing was done. The registry was limited to data collection related to subjects' usual medical care, and adverse event data were not collected. Data were collected by the primary health-care provider in the office or clinic setting.
Data were entered into a centralized electronic database maintained by the Synagis Outcomes Registry Coordinating Center. Integrity of the data was maintained through computerized edit checks, reports of missing data elements and forms distributed to the study sites for resolution continuously through the RSV season. Databases were locked for final analysis at the conclusion of each RSV season after final resolution of outstanding data items.
Statistical analysis
All analyses were exploratory. Data analyses included the examination of demographics and clinical characteristics at enrollment, compliance with the injection regimen, the RSV hospitalization rate and risk factors for RSV hospitalizations. Qualitative variables were described in absolute numbers and percentages for the entire cohort, by RSV season, and by gestational age.
Compliance with the injection regimen was defined in two ways. The first definition compared the actual number of injections with the expected number received based on the month that the first injection was administered. 18 For example, patients who received their first injection in November were expected to receive five injections. Patients who received their first injection in February would be expected to receive only two injections through March. Any patient who received five or more doses was included in the analysis as compliant. The second definition included subjects receiving at least two doses and was calculated as the proportion of subjects who received all palivizumab doses within 35 days of the previous dose.
The confirmed RSV hospitalization rate was calculated using only the incident RSV hospitalization for each subject within an RSV season; hospitalizations that occurred on or before 24 h of a subject's first palivizumab injection were excluded. 18 Odds ratios (ORs) for measuring the association between risk factors and RSVrelated hospitalizations were estimated by univariate logistic regression using the PROC LOGISTIC feature of SAS version 8 (SAS Institute Inc., Cary, NC, USA). w 2 -Test, ORs and confidence intervals were calculated for the relationship between hospitalizations and compliance (by both definitions). An a level of 0.05 was selected as the cutoff for statistical significance.
Results
Over the four seasons, 19 548 enrollments were recorded, with 1047 subjects (5.4%) enrolled for more than one season and counted as separate enrollments. Site data are shown by season in Table 1 . More than 99% of subjects enrolled had outcome and injection data captured for analysis. All-cause mortality reported during the follow-up period was 8 Most subjects (56.0%) were white, received palivizumab when they were p1 year of age (83.9%) and had a birth weight <2500 g (82.6%; Supplementary Table S1 ). The most common medical or environmental factors associated with RSV prophylaxis were childcare attendance by the subject or other household children For the cumulative data across all four seasons, 40.0% of infants were born before 32 weeks' gestation, 47.7% between 32 and 35 weeks' gestation, and 12.3% after 35 weeks' gestation (Supplementary Table S1 ). The percentage of infants born between 32 and 35 weeks' gestation remained similar over the four seasons (45.2 to 49.1%), whereas the percentage born after 35 weeks' gestation nearly doubled from the first (8.1%) to the fourth season (15.1%). This finding is likely related to completion of the trial in 2003, showing effective use of palivizumab in infants with hemodynamically significant CHD.
14 In addition to gestational age, the most prevalent risk factor for RSV infection among all gestational age groups was child-care attendance (subject or other household children; Table 2 ). Among infants born before 32 weeks' gestation, CLD was the second most common risk factor (38.6%). A history of CHD was more common in subjects born after 35 weeks' gestation (29.4%) compared with those born before 32 weeks' gestation (6.0%) or between 32 and 35 weeks' gestation (3.5%; Table 2 .1% were reported as having congenital airway abnormalities or severe neuromuscular disorders. The incidence of these conditions was similar among gestational age categories; 40.0% were born before 32 weeks' gestation, 30.0% were born at 32 to 35 weeks' gestation and 30.0% were born after 35 weeks' gestation.
Confirmed RSV hospitalizations
The confirmed RSV hospitalization rate over the four seasons was 1.3% for subjects prophylactically treated with palivizumab for whom follow-up information was available (n ¼ 19 474). The percentage of subjects hospitalized for a confirmed RSV infection decreased over the observation period from 2. Similarly, RSV hospitalization rates for subjects on Medicaid who received their dose at home were 0.6% (5 of 858) vs 1.6% (126 of 8070) for those who received their dose in a clinic or office (P ¼ 0.02). The distribution of hospitalizations during each season followed the typical pattern of RSV infection, generally peaking in January, 21 and was similar from season to season. Of note, a significant association was observed between hospitalizations and injection number in compliant subjects (definition 2), with lower numbers of injections associated with higher numbers of hospitalizations (P<0.0001). Over the four seasons, 31% of hospitalizations occurred between the first and second injections, 25% between the second and third injections and 19% between the third and fourth injections. Between the fourth and fifth injections, the percentage of hospitalizations dropped to 11%.
Supplementary Table S2 describes several factors associated with the risk for RSV hospitalizations. The likelihood of hospitalization was significantly higher for (1) boys vs girls (P ¼ 0.002), (2) singletons vs multiple birth subjects (P ¼ 0.03), (3) those born before 32 weeks' gestation vs those born after 35 weeks' gestation (P ¼ 0.02), (4) those with a history of CLD or CHD vs those without these conditions (Pp0.03 for both), (5) Medicaid recipients vs non-Medicaid recipients (P<0.0001) and (6) subjects from households with >2 children vs households where the subject was the only child (P ¼ 0.003). Based on data from the last two seasons, subjects having congenital airway abnormalities or neuromuscular disease had significantly higher rates of RSV hospitalization than those without either disorder (P<0.0001; Supplementary Table S2) . 
Compliance with dosing
Compliance rates, as defined by the appropriate number of doses, were similar throughout the observation period and ranged from 79.9 to 82.7% through all four seasons. Furthermore, 65.2 to 69.5% of subjects received each dose within 35 days of the previous injection. Overall, 59.3% of subjects were compliant by both definitions. Subjects who received palivizumab at home (n ¼ 1226) were significantly more compliant for both evaluations than those who received doses in a clinic or office (n ¼ 17 641) (88 vs 81% and 76 vs 69%, respectively, P<0.0001). In addition, compliance among Medicaid enrollees was significantly higher for those who received palivizumab at home (n ¼ 858) compared with the clinic or office (n ¼ 8070) for both definitions (90 vs 76% and 75 vs 61%, respectively, P<0.0001).
There was no significant association between compliance, as defined by the number of expected injections, and RSV hospitalizations. However, those who were compliant, as defined by receipt of all palivizumab doses within 35 days of the previous dose, had a significantly lower OR for RSV hospitalization compared with those who were noncompliant (OR, 0.702; 95% confidence interval, 0.543 to 0.913). Noncompliance, using this definition, was also associated with a significantly higher proportion of RSV hospitalizations compared to compliance (1.65 vs 1.16, P ¼ 0.0072).
Discussion
The Palivizumab Outcomes Registry is one of the largest and most detailed pediatric registries available, consisting a cohort of nearly 20 000 US infants and young children who received palivizumab prophylaxis, with standardized demographic and hospitalization data prospectively collected over four RSV seasons (2000 to 2001 through 2003 to 2004). The registry data describe post-licensure use of palivizumab in premature infants and those with wellrecognized contributing factors for RSV infection. The low infection rates reported in this registry are consistent with controlled clinical trial data. 13 Many of the characteristics that were included on our data forms were selected on the basis of indications for palivizumab prophylaxis listed in the 1998 AAP guidelines. 15 Use of palivizumab was generally consistent with the AAP guidelines at the time of enrollment 15, 16 and published literature on potential risk factors for RSV morbidity, such as prematurity and child-care attendance, 8 and low birth weight (LBW; <2500 g). 22 ,23 Based on cumulative data, approximately 90% of infants were premature, 83% had LBW and 47% were enrolled in child-care or were exposed to another child in the household who attended child care. The definition of child-care attendance was left to the discretion of each site. The rate of child-care enrollment may be lower in the first season (22.5%) compared to the rate in later seasons (47 to 51%) because of changes in the method of data collection by the registry (Supplementary Table S1 ). In the first season, the question about child-care enrollment made no distinction between subjects and other children in the household. In subsequent seasons, the question was modified to distinguish child-care attendance of the subject vs siblings. Thus, in the first season, individuals who completed the form may have been reporting information only for the subject and not for other children in the home. Our data suggest that physicians provided prophylaxis to infants within each gestational age category, and thus considered these infants to be at increased risk of severe RSV. For example, nearly 80% of registry infants born at 32 to 35 weeks' gestational age had LBW, whereas national vital statistics indicate that only 47% of US infants born at 32 to 35 weeks are LBW. 24 Physicians may have selected to provide prophylaxis to infants in this gestational age cohort because of LBW or other factors, such as child-care attendance or tobacco smoke exposure. The number of infants with CHD more than doubled from the first to the fourth season, with physicians listing this diagnosis as the most common reason for prophylaxis in the gestational age group older than 35 weeks. This change most likely reflects study findings showing the benefits of palivizumab prophylaxis in infants with CHD that were published during the last season of the registry, 14 with subsequent addition of this indication to the palivizumab-prescribing information and inclusion in the updated AAP guidelines. 16 The primary benefit of palivizumab immunoprophylaxis in a high-risk population is a reduction in the rate of RSV-associated hospitalizations. 13, 25 In controlled clinical trials of high-risk subjects, RSV hospitalization rates were approximately 10% in infants given placebo and 5% in those given prophylaxis with palivizumab. 13, 14 In observational studies of subjects given prophylaxis with palivizumab, hospitalization rates ranged from 2 to 4%. [25] [26] [27] Although hospitalization rates for our observational registry data over the four seasons also were low, ranging from 0.7 to 2.9%, these rates may be underestimated because only those hospitalizations that were confirmed with virology testing were captured. For example, children may have been admitted to the hospital for bronchiolitis but not tested for RSV.
The highest hospitalization rates were observed during the first season. Notably, the percentage of subjects with a gestational age <32 weeks was higher in the first season than in the latter seasons, and palivizumab efficacy is known to be lower in this age group. 13 However, in subsequent years of the registry, hospitalization rates in this group of infants were comparable to hospitalization rates of other gestational age groups. In clinical practice, physicians may be more likely to prescribe palivizumab prophylaxis for children who are 32 to 35 weeks' gestational age outside of the guidelines because of concerns for risk factors such as LBW and tobacco smoke. We speculate that the decrease in hospitalization rates observed in the registry may reflect year-to-year variability in RSV epidemiology across seasons and geographic regions. 28, 29 Other potential sources of variation were changes in participating sites, physicians, and study populations, and disparity in hospital admission criteria and RSV testing practices over the four consecutive seasons. In the registry, the number of hospitalizations was not based on direct review of hospital discharge records, but rather on chart review in pediatricians' offices and ongoing contact with patient caretakers during the study period. Capturing hospitalizations in this manner was considered to be more reliable than collecting data directly from local hospital sites.
With data from across all four seasons, univariate analysis showed that risk factors for RSV hospitalization in infants that had undergone palivizumab prophylaxis (for example, CHD, CLD, >2 children in the household, gestational age <32 weeks, male sex, Medicaid insurance) were similar to the overall known risk factors for RSV hospitalization. 2, [4] [5] [6] 8 This finding is consistent with prelicensure data showing a smaller reduction in RSV-associated hospitalization rates in infants treated with palivizumab who were younger than 32 weeks' gestational age vs those who were 32 to 35 weeks' gestational age. 13 In addition to the aforementioned risk factors, analysis of data from the last two seasons also demonstrates that the risk of hospitalization is elevated for children with congenital airway abnormalities or severe neuromuscular disease, regardless of their gestational age, including infants born>35 weeks' gestation. However, current AAP guidelines recommend palivizumab prophylaxis only for infants with these conditions who are born at 32 to 35 weeks' gestational age. 16 Our data also indicate that subjects receiving RSV prophylaxis through home care demonstrated increased compliance and improved outcomes (for example, reduced number of RSV hospitalizations) compared to those receiving RSV prophylaxis in a clinic or office. Similar results were observed for subjects enrolled in Medicaid. Other benefits of home care include decreased exposure to RSV in the office and greater opportunity for RSV education with parents and caregivers. These results suggest that home care administration of palivizumab during the RSV season may be a preferred option for infants at high risk of RSV hospitalization.
In conclusion, the Palivizumab Outcomes Registry provides a post-licensure example of palivizumab utilization and clinical decision-making in the United States. Prospective data collected over 4 years show consistently low RSV-confirmed hospitalization rates in high-risk infants and children receiving palivizumab. Because registry data indicate that nearly half of palivizumab use occurs in infants between 32 and 35 weeks' gestational age, future studies should examine risk factors for hospitalization in this age group. Dr Cohen was an employee of MedImmune during the drafting stage of this paper. He is now with Jazz Pharmaceuticals, Palo Alto, CA, USA.
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